British drugmaker GSK has acquired Nuvalent, a Boston-based clinical-stage biopharmaceutical company focused on precisely targeted oncology therapies, for an equity value of $10.6 billion (~£8 billion).
Terveystalo, Finland’s second-largest private hospital group, is buying Silmäasema, a Finnish eye-care and optical retail company, for ~€574 million (partial share-swap deal). The seller is private equity firm CapMan Growth. €275 million of this will be paid in cash, and the rest will be funded through 36.5 million new Terveystalo shares.
HBI hosted a webinar this week on the topic of value creation in healthcare organisations. The discussion looked at how healthcare providers are using digital tools, operational improvements and AI to build more connected and scalable organisations. Missed the webinar? Watch the recoding here.
France will begin reimbursing anti-obesity medicines from mid-June 2026, becoming the first EU country to introduce public coverage for treatments including Wegovy and Mounjaro, produced by Danish pharma giant Novo Nordisk and American pharmaceutical company Eli Lilly respectively. The policy is intended to prioritise high-risk patients rather than general weight management. Access will be limited to patients with severe obesity, defined as a BMI of at least 40, or at least 35 where accompanied by conditions such as type 2 diabetes or cardiovascular disease.
The global healthcare M&A landscape in 2026 sits at an unusual juncture. The wider economy is facing a lot of headwinds and feels increasingly uncertain, whilst the usual private equity strategies aren’t working as smoothly as before. Healthcare is still seen as one of the strongest sectors to invest in around the world, however, and may even benefit from the shift away from software and tech-enabled services.
Finland-based pan-European healthcare group Mehiläinen is buying pan-Nordic outpatient group Aleris from private equity firm Triton, marking Mehiläinen’s entry into Norway and Denmark. The combined group will have €3.7 billion revenue and be present in nine countries, making it Europe’s largest outpatient-focused healthcare group.
California-based private equity and credit firm Ares Management is joining as a new financing partner for Linimed Gruppe, Germany’s largest provider of out-of-hospital intensive care. It will invest alongside existing lenders global asset management firm BlackRock and Hamburg-based investment firm Berenberg, while London-based private equity firm GHO Capital remains the company’s majority shareholder.
European healthtech group Doctolib has entered the UK market through the acquisition of London-based startup Medicus. The company plans to invest over £100 million (~$136 million) in the UK as part of its expansion.
Pan-European private equity firm Astorg is acquiring American medical device maker Thermo Fisher Scientific’s microbiology business for around $1 billion. Astorg plans to run the business as a standalone platform, focusing on organic growth, selective M&A, and operational improvements.
Barmer, Germany’s second largest non-profit statutory health insurer with around 8.7 million members, has partnered with Austrian femtech company Hello Inside to offer its metabolic health programme as a reimbursed prevention service. Mario Aichlseder, Hello Inside’s co-founder, explained to us how this an important step in demonstrating that the company’s offering is a healthcare product, rather than a wellness product.
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.
